Lipfendra, the first once-daily oral PCSK9 inhibitor, was shown to reduce LDL cholesterol by roughly 56% to 60% when combined with statins.

https://www.foxnews.com/health/game-changing-cholesterol-pill-wins-fda-approval-cutting-ldl-nearly-60